Average Insider

Where insiders trade, we follow

$GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Healthcare
Sector
Biotechnology
Industry
Thomas D. Zindrick
CEO
24
Employees
$1.82
Current Price
$106.54M
Market Cap
52W Low$1.77
Current$1.820.9% above low, 99.1% below high
52W High$7.50

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00--All Sells
Sells33$9,023.784,425
2 monthsBuys00--All Sells
Sells33$9,023.784,425
3 monthsBuys00--All Sells
Sells36$155,693.4758,828
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 3, 2026
Cappello Joseph
Chief Technical Officer
Sale668$2.04$1,362.92View Details
Nov 3, 2026
Zindrick Thomas
President and CEO
Sale3,089$2.05$6,317.31View Details
Nov 3, 2026
Yu Yong
Chief Scientific Officer
Sale668$2.01$1,343.55View Details
Aug 31, 2026
Cappello Joseph
Chief Technical Officer
Sale10,257$2.74$28,112.39View Details
Aug 31, 2026
Zindrick Thomas
President and CEO
Sale34,463$2.67$91,899.04View Details
Aug 31, 2026
Yu Yong
Chief Scientific Officer
Sale9,683$2.75$26,658.27View Details
18 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 18, 2026
EPS
Estimated-$0.19
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Nov 16, 2026
EPS
Estimated-$0.20
Actual-$0.23
Miss
Revenue
EstimatedN/A
ActualN/A
Nov 11, 2026
EPS
Estimated-$0.19
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Nov 4, 2026
EPS
Estimated-$0.20
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.11.1